Picture of Divi's Laboratories logo

DIVISLAB — Divi's Laboratories News Story

0.000.00%
in flag iconLast trade - 00:00
HealthcareConservativeLarge CapHigh Flyer

India's Divi's Labs falls after data from Pfizer's COVID-19 antiviral pill

** Indian drugmaker's shares  DIVI.NS  slump as much as 8.8%
to 4,747.80 rupees, on track for worst day in over 1-1/2 years
    ** U.S.-based pharma giant Pfizer  PFE.N  on Friday said its
antiviral pill slashes risk of severe COVID-19 by 89%,
surpassing Merck & Co's  MRK.N  pill, molnupiravir which halves
the chance of hospitalization or death for adults at risk of
severe COVID-19  urn:newsml:reuters.com:*:nL1N2RW0N5
    ** Analysts at Jefferies say that Pfizer's drug could pose a
risk to Divi's prospects as it makes the active pharmaceutical
ingredient (API) of molnupiravir 
    ** Jefferies also added that the company may not be immune
to rising raw material prices in coming quarters and does not
see its margins improving 
    ** Divi's which has already begun supplying molnupiravir
didn't specify the reason for sluggishness in their generic APIs
business (second quarter in a row) during earnings call - Ambit
Capital 
    ** Continued sluggishness in the generic API segment could
pose risk to Divi's near-term forecast and valuations - Ambit 
    ** On Friday, Divi's reported 17% rise in Q2 consolidated
net profit to 6.06 bln rupees ($81.68 million)
    ** Despite session's drop, DIVI stock is still up ~24% YTD


($1 = 74.1900 Indian rupees)

 (Reporting by Shivani Singh in Bengaluru)
 ((ShivaniSingh1@thomsonreuters.com; +91 89 6969 2349))

Recent news on Divi's Laboratories

See all news